Navigation Links
DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
Date:8/11/2008

PARSIPPANY, N.J., Aug. 12 /PRNewswire/ -- DSM Biologics and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) today announced the signing of a Biopharmaceutical Manufacturing Agreement covering process development and cGMP manufacturing of MOR202. MOR202 is a fully human HuCAL(R) antibody, directed against CD38, a promising target for the treatment of multiple myeloma. DSM Biologics will manufacture MOR202 in its cGMP facilities in Groningen, the Netherlands. Further financial details on this agreement were not disclosed.

"Based on the positive experiences we have gained with the PER.C6(R) cell line and DSM's manufacturing capabilities within our MOR103 lead program, we have chosen to continue to use this platform for MOR202," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys.

"We are very pleased that MorphoSys is extending its business partnership with DSM Biologics as their preferred manufacturing partner after our highly successful collaboration on the MOR103 program," says Marcel Lubben, VP Marketing & Sales at DSM Biologics. "It is exciting how well the combination of our two strong platforms works for fully human antibodies," Lubben added.

About PER.C6(R) Technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V
'/>"/>

SOURCE DSM Biologics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Pharma, Inc.,(Nasdaq: IDMI ), a biotechnology company focused ... Timothy P. Walbert,president and chief executive officer, will present ... Diego on Thursday, November 1, 2007,at 2 p.m. PDT ... webcast of the presentation will be available live and ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) has announced the ... Financial and Accounting Officer.,Immunosyn,s former Chief Financial and ... as the company,s Chairman of the Board and,further ... believe that the platform technology and its resulting,biopharmaceutical ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
Cached Biology Technology:IDM Pharma to Present at BIOCOM Investor Conference 2IDM Pharma to Present at BIOCOM Investor Conference 3Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2
(Date:9/2/2014)... study published in the September 2014 issue of ... Child and Adolescent Psychiatry found that children ... an increased risk of developing diabetes if they ... the nationwide Danish registers, a group of researchers ... University Hospital, Denmark, studied 48,299children and adolescents with ...
(Date:9/2/2014)... N.C. -- When you accidentally touch a hot oven, ... the basic neural circuits involved in sensing and responding ... the molecular players. , Duke researchers have made a ... involved in pain in worms, and have built a ... 2 in Nature Communications , may help direct ...
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Nature's tiny engineers 2Nature's tiny engineers 3
... Jan. 7, 2014 DigitalPersona, Inc., a trusted ... that its TouchChip® TCS1 sensor is the only ... the Ministry of Public Security under general technical ... for the China Resident Identity Card.  Miaxis Biometrics ...
... FL (January 6, 2014) Of the 1.9 million species ... 1.3 million are invertebrates. They have served as model organisms ... of the important role of invertebrates in science including sea ... and Loligo for neurobiology research, the fruit fly ...
... 2014) Autism Speaks, the world,s leading autism science ... $2.7 million for the funding of 13 new research ... address Autism Speaks, Early Access to Care initiative to ... to high-quality early intervention for all children affected by ...
Cached Biology News:Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 2Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 3New organization brings together top researchers to sequence the genomes of invertebrates 2New organization brings together top researchers to sequence the genomes of invertebrates 3Autism Speaks awards nearly $2.7 million for new research projects 2Autism Speaks awards nearly $2.7 million for new research projects 3Autism Speaks awards nearly $2.7 million for new research projects 4
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: